Sobi has come to an agreement with TiGenix for the early termination of their existing commercial relationships and will return the distribution rights for ChondroCelect to TiGenix.
ChondroCelect treatment has been available since 2011, and an important additional tool when it comes to treatment of cartilage defects Sobi has during the time as distributor for ChondroCelect experienced a significant belief in the product and it has been an appreciated treatment alternative. Despite this reimbursement of Chondrocelect has declined in several key countries. Hence, Sobi has in mutual agreement with TiGenix decided to return the distribution rights of ChondroCelect to TiGenix.
TiGenix has decided to withdraw the product from the market as of November 30, 2016.